At a glance
- Originator Eisai Co Ltd
- Class Anti-ischaemics; Anticoagulants; Coumarins
- Mechanism of Action Vitamin K epoxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Thromboembolism
Most Recent Events
- 01 Dec 2011 Launched for Thromboembolism (in children and adolescents) in Japan (PO, granule formulation)
- 01 Dec 2011 Launched for Thromboembolism in Japan (PO, granule formulation)
- 31 Oct 2011 Registered for Thromboembolism (paediatric granule formulation) in Japan (PO)